Alpha-1-antitrypsin (a 1 -antitrypsin) is the archetypal member of the serine proteinase inhibitor or serpin superfamily. The most common severe deficiency variant is the Z allele, which results in the accumulation of mutant protein within hepatocytes. This 'protein overload' causes neonatal hepatitis, cirrhosis and hepatocellular carcinoma. The lack of circulating plasma a 1 -antitrypsin results in early-onset panlobular emphysema. The mechanism underlying the deficiency of Z a 1 -antitrypsin is due to an aberrant conformational transition within the protein and the formation of chains of polymers that tangle within the secretory pathway of hepatocytes. This mechanism also underlies the plasma deficiency of other members of the serpin superfamily to cause a class of diseases called the serpinopathies. Specifically mutant alleles of antithrombin, C1-inhibitor and a 1 -antichymotrypsin have been reported that favour the spontaneous formation of polymers and the retention of protein within hepatocytes. The consequent lack of plasma antithrombin, C1-inhibitor and a 1 -antichymotrypsin results in thrombosis, angio-oedema and emphysema, respectively. Moreover, the polymerisation of mutants of neuroserpin results in the retention of polymers within neurones to cause the inclusion body dementia, familial encephalopathy with neuroserpin inclusion bodies or FENIB. We review here the genetic and molecular basis and clinical features of a 1 -antitrypsin deficiency, and show how this provides a platform to understand the other serpinopathies. Keywords: a 1 -antitrypsin; a 1 -antichymotrypsin; antithrombin; C1-inhibitor; neuroserpin; serpins; serpinopathies
Alpha-1-antitrypsinGene structure and common mutations Alpha-1-antitrypsin (a 1 -antitrypsin) is a 394 amino acid, 52 kDa, acute-phase glycoprotein synthesised by the liver and macrophages and present in the plasma at a concentration of 1.5 -3.5 g/l. It functions as an inhibitor of a range of proteolytic enzymes, but its primary role is to inhibit the enzyme neutrophil elastase. a 1 -Antitrypsin is subject to genetic variation resulting from mutations in the 12.2 kb, 7-exon gene at q31 -31.2 on chromosome 14.1 Over 75 allelic variants have been reported and classified using the protease inhibitor (PI) nomenclature that assesses a 1 -antitrypsin mobility in isoelectric focusing analysis.
2Normal a 1 -antitrypsin migrates in the middle (M) and variants are designated A -L if they migrate faster than M, and N -Z if they migrate more slowly. The most clinically relevant variants are the S (Glu264Val) and Z (Glu342Lys) alleles and the uncommon Null alleles that result from point mutations that introduce premature stop codons.